RJA
NSPR icon

Raymond James & Associates’s InspireMD NSPR Stock Holding History

Raymond James & Associates’s Portfolio NSPR Stock Details NSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,333
Closed -$24K – 4161
2021
Q1 		$24K Buy
+2,333
New +$27.8K ﹤0.01% 3909

Other funds holding NSPR

Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
HCM
Hollencrest Capital Management Newport Beach, California $2.7B AUM 23.62% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Raymond James & Associates's NSPR Position: Q2 2021 in Review

Raymond James & Associates sold out of InspireMD (NSPR) in Q2 2021, closing a stake of 2,333 shares — an estimated $24K sold.

Raymond James & Associates first reported a position in NSPR in Q1 2021 and held it in 1 quarter. The position peaked at $24K in Q1 2021. 16 funds tracked by Wall St. Rank hold NSPR as of Q2 2021.

  • Raymond James & Associates reported no remaining InspireMD position as of Q2 2021 after selling out during the quarter.
  • Raymond James & Associates sold 2,333 InspireMD shares in Q2 2021, an estimated $24K.
  • Raymond James & Associates first reported a position in InspireMD in Q1 2021 and held it in 1 quarter.
  • Raymond James & Associates's InspireMD position peaked at $24K in Q1 2021.
  • 16 funds tracked by Wall St. Rank held InspireMD as of Q2 2021.

Based on Raymond James & Associates's 13F filing for Q2 2021, filed 11 Aug 2021.